Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly sales of $12.768 million which beat the analyst consensus estimate of $5.420 million by 135.57 percent. This is a 38.54 percent increase over sales of $9.216 million the same period last year.
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly sales of $12.768 million which beat the analyst consensus estimate of $5.420 million by 135.57 percent. This is a 38.54 percent increase over sales of $9.216 million the same period last year.
Comments